PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Negative net income growth while TRVN stands at 38.72%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
24.17%
D&A growth well above TRVN's 17.93%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
100.00%
Some yoy growth while TRVN is negative at -104.27%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-9.33%
Negative yoy SBC while TRVN is 43.62%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-80.33%
Both reduce yoy usage, with TRVN at -344.49%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
Negative yoy AP while TRVN is 66.32%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-249.09%
Both reduce yoy usage, with TRVN at -104.66%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-101.42%
Both negative yoy, with TRVN at -10.23%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-72.30%
Negative yoy CFO while TRVN is 11.87%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-455.28%
Both yoy lines negative, with TRVN at -38.46%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have some outflow growth while TRVN is negative at -31.34%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-427.62%
Both yoy lines negative, with TRVN at -32.17%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
Stock issuance far above TRVN's 504.22%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.